The U.S. Federal Trade Commission (FTC) has requested more information from AbbVie and Allergan on their $63 billion deal.
In June, AbbVie announced its intention to buy Allergan for approximately $63 billion. The move is meant to reduce its reliance on the blockbuster Humira as it will face patents ending in the U.S. in 2023.
However, the deal – which combines two of the world’s biggest pharma companies – has faced high scrutiny by a dozen advocacy groups and unions, who have petitioned the FTC to block the purchase.
AbbVie and Allergan say they are cooperating fully with the FTC and continue to expect to close the transaction in early 2020.
Read the press release